Previous 10 | Next 10 |
home / stock / zldpf / zldpf news
Press Release – No. 2 / 2024 Zealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financial results Copenhagen, Denmark, February 20, 2024 – a Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on t...
Company announcement – No. 4 / 2024 Zealand Pharma major shareholder announcement: J O Hambro Capital Management Copenhagen, Denmark, 17 January 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biote...
Company announcement – No. 3 / 2024 Zealand Pharma completes registration of capital increase NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA, EXCEPT AS PERMITTED BY APPLICABLE LAW. ...
Company announcement – No. 2 / 2024 Zealand Pharma major shareholder announcement: Avoro Capital Advisors LLC Copenhagen, Denmark, 10 January 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechn...
Company announcement – No. 1 / 2024 Zealand Pharma announces directed issue and private placement for gross proceeds of DKK 1.45 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA, EX...
Press Release – No. 1 / 2024 Zealand Pharma to participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference on January 4th Copenhagen, Denmark, January 2, 2024 – Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the disc...
Company announcement – No. 45 / 2023 U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyperinsulinism for up to three weeks of dosing due to inspection findings at third-party manufacturing facility The CRL is related to defic...
Press release – No. 18 / 2023 Zealand Pharma submits New Drug Application to the US FDA for glepaglutide in short bowel syndrome Copenhagen, Denmark, December 22, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078), a biotech...
Press release No. 17 / 2023 Zealand Pharma enters into EUR 90 million finance agreement with the European Investment Bank Copenhagen, Denmark, December 22 , 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078) a biotechnology com...
Press release – No. 16 / 2023 Zealand Pharma to highlight obesity pipeline at R&D Event on December 5 Event to be hosted by company management and feature key external scientific and clinical experts Copenhagen, Denmark, December 4, 2023 – Zealand...
News, Short Squeeze, Breakout and More Instantly...
Zealand Pharma A/S Ord Company Name:
ZLDPF Stock Symbol:
OTCMKTS Market:
JD.com Inc. (JD) is expected to report $0.56 for Q1 2024 Volkswagen AG (VLKAF) is expected to report for Q1 2024 CalAmp Corp. (CAMP) is expected to report for Q4 2024 Sonic Foundry Inc. (SOFO) is expected to report for Q2 2024 Moatable Inc ADR (R2RS:MU) is expected to report for Q...
Company announcement - No. 26 / 2024 Zealand Pharma Announces Financial Results for the First Quarter of 2024 Strong performance in the first quarter of 2024 paving the way for important data read-outs across differentiated obesity assets in the second quarter. Strong toplin...
Press Release – No. 4 / 2024 Zealand Pharma conference call on May 16 at 2pm CET (8am ET) to present first quarter 2024 financial results Copenhagen, Denmark, May 9, 2024 – Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the discov...